Australia's most trusted
source of pharma news
Saturday, 22 November 2025
Posted 21 November 2025 PM
Novo Nordisk’s failure to pay a AUD$275 patent maintenance fee has opened up the Canadian semaglutide market to generics – and Sandoz is making the most of it. It has submitted a biosimilar for approval and hopes to launch there next year.
“No one’s actually got an approval yet, but certainly we would expect to see entrance in that market in Q1 [or] Q2 next year,” Sandoz CEO Richard Saynor said at the Financial Times Global Pharma and Biotech Summit last week.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.